Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
Q1 2026 earnings • in 3 days
See details
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
24,77 USD
+0,32%
(+0,080) 1D
24,69 USD
-0,32% (-0,080)
After hours
Closed: 1-май, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
24,90 USD
High
25,12 USD
Low
24,36 USD
Mkt. cap
2,44 млд
Avg. vol.
2,04 млн
Volume
1,41 млн
52-wk high
42,37 USD
52-wk low
18,29 USD
EPS
-5,83 USD
Beta
0,25
Shares outstanding
98,32 млн
No. of employees
1 миң
News stories
From sources across the web
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1,37 миң
Founded2010
HeadquartersНовато, Калифорния, Америка Кошмо Штаттары
Sector-
Websiteultragenyx.com
Next call 3 күндөн кийин
5-май, шейш., 17:00
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-1,46 est.)USD
Revenue / Estimate
-/ (158,41 млн est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
139,29 млн
166,50 млн
159,93 млн
207,28 млн
Cost of goods sold
194,43 млн
187,74 млн
244,20 млн
232,62 млн
Cost of revenue
194,43 млн
187,74 млн
244,20 млн
232,62 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87,80 млн
86,65 млн
86,62 млн
87,94 млн
Operating expense
87,80 млн
86,65 млн
86,62 млн
87,94 млн
Total operating expenses
282,23 млн
274,38 млн
330,82 млн
320,56 млн
Operating income
-142,94 млн
-107,89 млн
-170,89 млн
-113,28 млн
Other non operating income
837,00 миң
2,14 млн
-1,04 млн
-934,00 миң
EBT including unusual items
-149,77 млн
-114,00 млн
-179,54 млн
-127,69 млн
EBT excluding unusual items
-149,61 млн
-114,00 млн
-180,22 млн
-127,17 млн
Income tax expense
1,31 млн
947,00 миң
873,00 миң
870,00 миң
Effective tax rate
-0,87%
-0,83%
-0,49%
-0,68%
Other operating expenses
-
-
-
-
Net income
-151,08 млн
-114,95 млн
-180,41 млн
-128,56 млн
Net profit margin
-108,46%
-69,04%
-112,81%
-62,02%
Earnings per share
-1,57
-1,17
-1,81
-1,29
Interest and investment income
6,83 млн
5,79 млн
5,86 млн
6,51 млн
Interest expense
-14,34 млн
-14,04 млн
-14,15 млн
-19,47 млн
Net interest expenses
-7,51 млн
-8,25 млн
-8,28 млн
-12,96 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-133,95 млн
-99,27 млн
-162,28 млн
-104,50 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer